Author(s):
Shaik Mateena, B.V. Ramana
Email(s):
Shaikmateena2002@gmail.com
DOI:
10.52711/2231-5659.2026.00036 
Address:
Shaik Mateena1, B.V. Ramana2
1Pharm D 3rd Year, Dr. K.V. Subbareddy Institute of Pharmacy, Jawaharlal Nehru Technological University. Ananthapur. Andhrapradesh, India.
2Associate Principal, Branch of Pharmacology, Dr. K.V. Subbareddy Institute of Pharmacy, Jawaharlal Nehru Technological University, Ananthapur. Andhrapradesh, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
A revolutionary approach to healthcare, personalized medicine replaces the conventional "one size fits all" approach with focused preventative and treatment plans based on a person's genetic composition, lifestyle, and environmental circumstances. By forecasting disease risks, directing therapy selection, and creating individualized preventative strategies, this developing discipline optimizes patient outcomes by leveraging insights from genomes and other biological data sources. Healthcare professionals can create personalized treatment regimens that are safer and more successful than generic options by using genetic testing to better understand a patient's susceptibility to diseases and how they will likely respond to particular therapies. By enabling the identification of disease subtypes and treatment responses unique to each patient, the Human Genome Project has greatly advanced the field of personalized medicine. Applications include preventive measures for people with known genetic predispositions and targeted cancer treatments that target particular genetic alterations. This method reduces adverse medication reactions, improves disease identification, expedites drug development by minimizing trial-and-error prescribing, and increases therapeutic efficacy. Notwithstanding its potential, personalized medicine has drawbacks, such as exorbitant expenses, restricted availability in underdeveloped areas, legal restrictions, and moral dilemmas like data privacy and informed consent. Furthermore, an over-reliance on genetic data and unequal access could put holistic care at danger. However, as genomes, proteomics, and data analytics continue to progress, customized medicine is predicted to have a significant impact on healthcare in the future.
Cite this article:
Shaik Mateena, B.V. Ramana. A new Era of Targeted Treatment and Preventive Care. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(3):243-6. doi: 10.52711/2231-5659.2026.00036
Cite(Electronic):
Shaik Mateena, B.V. Ramana. A new Era of Targeted Treatment and Preventive Care. Asian Journal of Research in Pharmaceutical Sciences. 2026; 16(3):243-6. doi: 10.52711/2231-5659.2026.00036 Available on: https://www.ajpsonline.com/AbstractView.aspx?PID=2026-16-3-5
REFERENCES:
1. Shah GL, Majhail N, Khera N, Giralt S. Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. Curr Hematol Malig Rep. 2018 doi: 10.1007/s11899-018-0444-z. [DOI] [PMC free article] [PubMed] [Google
2. Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015;520(7549):609–11. Doi: 10.1038/520609a.
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6366451/
4. https://www.genome.gov/genetics-glossary/Personalized-Medicine#:~:text=Personalized%20medicine%20is%20a%20fantastic,that%20kind%20of%20personalized%20approach
5. N.S. Abul-Husn, E.E. Kenny Personalized medicine and the power of electronic health records
6. Suwinski P., Ong C., Ling M.H.T., Poh Y.M., Khan A.M., Ong H.S. Advancing Personalized Medicine through the Application of Whole Exome Sequencing and Big Data Analytics. Front. Genet. 2019; 10:49. Doi: 10.3389/fgene.2019.00049.
7. https://www.sciencedirect.com/science/article/pii/S1098301513018615
8. https://www.medanta.org/patient-education-blog/insights-into-the-future-of-clinical-genetics-advances-and-emerging-technologies#:~:text=Genetic%20sequencing%20helps%20identify%20genetic%20mutations%20that,and%20improving%20our%20ability%20to%20prevent%20diseases
9. Altshuler D, Kruglyak L, Lander E. Genetic polymorphisms and disease. New England Journal of Medicine. 1998;338(22):1626
10. Vogenberg FR, Barash C Isaacson, Pursel M. Personalized medicine: Part 1: Evolution and development into theranostics. P T. 2010; 35:560–576
11. Abul-Husn NS, Owusu OA, Sanderson SC, Gottesman O, Scott SA. Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics and Personalized Medicine. 2014; 7:227–240. Doi: 10.2147/PGPM.S48887.
12. https://medlineplus.gov/lab-tests/pharmacogenetic-tests/#:~:text=Pharmacogenetic%20testing%20provides%20information%20about,a%20type%20of%20precision%20medicine
13. Washington D.C., The National Academies Press. National Research Council; Washington, DC: 2011. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease.
14. https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies#:~:text=Targeted%20therapy%20is%20a%20type,Learn%20more%20about%20monoclonal%20antibodies
15. Sairamesh J and Rossbach M: An economic perspective on personalized medicine. HUGO J, 7:12013
16. Check Hayden E. Promising gene therapies pose million-dollar conundrum. Nature. 2016;534(7607):305–6. Doi: 10.1038/534305a.
17. Topol, E. J. High‐performance medicine: the convergence of human and artificial intelligence. Nat. Med. 25, 44–56 (2019).
18. Ozawa, S., Evans, J. P., Kirchhoff, K. T., and Larson, E. B., Pharmacogenomic testing: A systematic review of the economic evidence for its effectiveness on patient outcomes. Personalized Medicine,2018,15(3), 245–257.
19. Suwinski P., Ong C., Ling M.H.T., Poh Y.M., Khan A.M., Ong H.S. Advancing Personalized Medicine through the Application of Whole Exome Sequencing and Big Data Analytics. Front. Genet. 2019; 10:49. Doi: 10.3389/fgene.2019.00049.
20. https://www.mrmed.in/health-library/health-care/personalized-medicine-india
21. Joly Y, Knoppers BM, editors. Routledge Handbook of Medical Law and Ethics. Routledge; New York: 2015. MA: Privacy and Confidentiality; pp. 52–66.
22. Vogenberg FR, Barash C Isaacson and Pursel M: Personalized medicine: Part 1: Evolution and development into theranostics. P T,2010,35,560–576
23. https://www.nrces.in/download/files/pdf/Poster_Standardizing_Genomic_Data.pdf#:~:text=Integrating%20genomic%20data%20into%20Electronic%20Health%20Records,use%20of%20genomic%20information%20in%20clinical%20settings
24. https://www.mdpi.com/1999-4923/16/3/332
25. https://www.ncbi.nlm.nih.gov/books/NBK132157/#:~:text=Genetic%20discrimination.,genetics%20as%20a%20health%20tool
26. Peterson RE, Edwards AC, Bacanu SA, Dick DM, Kendler KS, and Webb BT (2017). The utility of empirically assigning ancestry groups in cross‐population genetic studies of addiction. The American Journal on Addictions, 26(5), 494–501. [DOI] [PMC free article] [PubMed] [Google Scholar
27. Avinun R (2019). Educational Attainment Polygenic Score is Associated with Depressive Symptoms via Socioeconomic Status: A Gene-Environment-Trait Correlation. bioRxiv, 727552.
28. https://www.sciencedirect.com/science/article/pii/S2444569X24001379
29. Abul-Husn N.S., Kenny E.E. Personalized medicine and the power of electronic health records. Cell. 2019; 177:58–69. Doi: 10.1016/j.cell.2019.02.039
30. Wilson I.B., Cleary P.D. Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA. 1995; 273:59–65. Doi: 10.1001/jama.1995.03520250075037
31. Alizadeh AA et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
32. Rajpurkar P., Chen E., Banerjee O., Topol E.J. AI in health and medicine. Nat. Med. 2022; 28:31–38. Doi: 10.1038/s41591-021-01614-0.
33. https://www.ncbi.nlm.nih.gov/books/NBK2682/
34. Kim, E., Yang, J., Park, S. et al. Factors Affecting Success of New Drug Clinical Trials. Ther Innov Regul Sci 57, 737–750 (2023). https://doi.org/10.1007/s43441-023-00509-1
35. Elliott RA, Camacho E, Jankovic D, et al. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf 2021; 30:96–105. 10.1136/bmjqs-2019-010206
36. Check Hayden E. Promising gene therapies pose million-dollar conundrum. Nature. 2016;534(7607):305–6. Doi: 10.1038/534305a.
37. Shah GL, Majhail N, Khera N, Giralt S. Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. Curr Hematol Malig Rep. 2018 doi: 10.1007/s11899-018-0444
38. Arendt D., Musser J.M., Baker C.V.H., Bergman A., Cepko C., Erwin D.H., Pavlicev M., Schlosser G., Widder S., Laubichler M.D., et al. The origin and evolution of cell types. Nat. Rev. Genet. 2016; 17:744–757. Doi: 10.1038/nrg.2016.127. [DOI
39. Eichelbaum M., Ingelman-Sundberg M., Evans W.E. Pharmacogenomics and Individualized Drug Therapy. Annu. Rev. Med. 2006; 57:119–137. Doi: 10.1146/annurev.med.56.082103.104724.